Developing multi-target therapeutics to fine-tune the evolutionary dynamics of the cancer ecosystem

Frontiers in Pharmacology

Volumn 6, Issue SEP, 2015, Pages

  Xie, Lei ^a,b   Bourne, Philip E ^c  

^a CITY UNIVERSITY OF NEW YORK   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Cancer evolution; Cell cell communication; Multi target drug; Non linear dynamic system; Polypharmacology

Indexed keywords

ANTINEOPLASTIC AGENT; CLOZAPINE; PROTEINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER STEM CELL; CELL COMMUNICATION; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG RESISTANCE; DRUG SELECTIVITY; DRUG TARGETING; HUMAN; MOLECULAR EVOLUTION; NEOPLASM; NONHODGKIN LYMPHOMA; NOTE; POLYPHARMACOLOGY; SIGNAL TRANSDUCTION; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84944714575     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2015.00209     Document Type: Note

References (40)

1. Aguirre-Ghiso, J. A. (2006). The problem of cancer dormancy: understanding the basic mechanisms and identifying therapeutic opportunities. Cell Cycle 5, 1740-1743. doi: 10.4161/cc.5.16.3165
2. An, G., Mi, Q., Dutta-Moscato, J., and Vodovotz, Y. (2009). Agent-based models in translational systems biology. Wiley Interdiscip. Rev. Syst. Biol. Med. 1, 159-171. doi: 10.1002/wsbm.45
3. Apsel, B., Blair, J. A., Gonzalez, B., Nazif, T. M., Feldman, M. E., Aizenstein, B., et al. (2008). Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat. Chem. Biol. 4, 691-699. doi: 10.1038/nchembio.117
4. Bordbar, A., Monk, J. M., King, Z. A., and Palsson, B. O. (2014). Constraint-based models predict metabolic and associated cellular functions. Nat. Rev. Genet. 15, 107-120. doi: 10.1038/nrg3643
5. Bozic, I., Reiter, J. G., Allen, B., Antal, T., Chatterjee, K., Shah, P., et al. (2013). Evolutionary dynamics of cancer in response to targeted combination therapy. Elife 2:e00747. doi: 10.7554/eLife.00747
6. Br�cher, B. L., and Jamall, I. S. (2014). Cell-cell communication in the tumor microenvironment, carcinogenesis, and anticancer treatment. Cell. Physiol. Biochem. 34, 213-243. doi: 10.1159/000362978
7. Carmi, Y., Spitzer, M. H., Linde, I. L., Burt, B. M., Prestwood, T. R., Perlman, N., et al. (2015). Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity. Nature 521, 99-104. doi: 10.1038/nature14424
8. Crystal, A. S., Shaw, A. T., Sequist, L. V., Friboulet, L., Niederst, M. J., Lockerman, E. L., et al. (2014). Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 346, 1480-1486. doi: 10.1126/science.1254721
9. Floor, S. L., Dumont, J. E., Maenhaut, C., and Raspe, E. (2012). Hallmarks of cancer: of all cancer cells, all the time? Trends Mol. Med. 18, 509-515. doi: 10.1016/j.molmed.2012.06.005
10. Gallaher, J., Cook, L. M., Gupta, S., Araujo, A., Dhillon, J., Park, J. Y., et al. (2014). Improving treatment strategies for patients with metastatic castrate resistant prostate cancer through personalized computational modeling. Clin. Exp. Metastasis 31, 991-999. doi: 10.1007/s10585-014-9674-1
11. Gao, M., and Skolnick, J. (2010). Structural space of protein-protein interfaces is degenerate, close to complete, and highly connected. Proc. Natl. Acad. Sci. U.S.A. 107, 22517-22522. doi: 10.1073/pnas.1012820107
12. Gatenby, R. A., Silva, A. S., Gillies, R. J., and Frieden, B. R. (2009). Adaptive therapy. Cancer Res. 69, 4894-4903. doi: 10.1158/0008-5472.CAN-08-3658
13. Gawad, C., Koh, W., and Quake, S. R. (2014). Dissecting the clonal origins of childhood acute lymphoblastic leukemia by single-cell genomics. Proc. Natl. Acad. Sci. U.S.A. 111, 17947-17952. doi: 10.1073/pnas.1420822111
14. Gerlinger, M., Horswell, S., Larkin, J., Rowan, A. J., Salm, M. P., Varela, I., et al. (2014). Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 46, 225-233. doi: 10.1038/ng.2891
15. Holohan, C., Van Schaeybroeck, S., Longley, D. B., and Johnston, P. G. (2013). Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 13, 714-726. doi: 10.1038/nrc3599
16. Hopkins, A. L., Mason, J. S., and Overington, J. P. (2006). Can we rationally design promiscuous drugs? Curr. Opin. Struct. Biol. 16, 127-136. doi: 10.1016/j.sbi.2006.01.013
17. Johnson, L. A., Scholler, J., Ohkuri, T., Kosaka, A., Patel, P. R., McGettigan, S. E., et al. (2015). Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci. Transl. Med. 7, 275ra22. doi: 10.1126/scitranslmed.aaa4963
18. Jubb, H., Higueruelo, A. P., Winter, A., and Blundell, T. L. (2012). Structural biology and drug discovery for protein-protein interactions. Trends Pharmacol. Sci. 33, 241-248. doi: 10.1016/j.tips.2012.03.006
19. Karr, J. R., Sanghvi, J. C., Macklin, D. N., Gutschow, M. V., Jacobs, J. M., Bolival, B. Jr., et al. (2012). A whole-cell computational model predicts phenotype from genotype. Cell 150, 389-401. doi: 10.1016/j.cell.2012.05.044
20. Keskin, O., Ma, B., and Nussinov, R. (2005). Hot regions in protein-protein interactions: the organization and contribution of structurally conserved hot spot residues. J. Mol. Biol. 345, 1281-1294. doi: 10.1016/j.jmb.2004.10.077
21. Kitano, H. (2007). A robustness-based approach to systems-oriented drug design. Nat. Rev. Drug Discov. 6, 202-210. doi: 10.1038/nrd2195
22. Korolev, K. S., Xavier, J. B., and Gore, J. (2014). Turning ecology and evolution against cancer. Nat. Rev. Cancer 14, 371-380. doi: 10.1038/nrc3712
23. Kurtova, A. V., Xiao, J., Mo, Q., Pazhanisamy, S., Krasnow, R., Lerner, S. P., et al. (2015). Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature 517, 209-213. doi: 10.1038/nature14034
24. Ledford, H. (2015). End of cancer-genome project prompts rethink. Nature 517, 128-129. doi: 10.1038/517128a
25. Lee, M. C., Lopez-Diaz, F. J., Khan, S. Y., Tariq, M. A., Dayn, Y., Vaske, C. J., et al. (2014). Single-cell analyses of transcriptional heterogeneity during drug tolerance transition in cancer cells by RNA sequencing. Proc. Natl. Acad. Sci. U.S.A. 111, E4726-E4735. doi: 10.1073/pnas.1404656111
26. Ma, B., and Nussinov, R. (2014). Druggable orthosteric and allosteric hot spots to target protein-protein interactions. Curr. Pharm. Des. 20, 1293-1301. doi: 10.2174/13816128113199990073
27. Mayor, R., and Carmona-Fontaine, C. (2010). Keeping in touch with contact inhibition of locomotion. Trends Cell Biol. 20, 319-328. doi: 10.1016/j.tcb.2010.03.005
28. McGranahan, N., and Swanton, C. (2015). Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell 27, 15-26. doi: 10.1016/j.ccell.2014.12.001
29. Mullard, A. (2012). Protein-protein interaction inhibitors get into the groove. Nat. Rev. Drug Discov. 11, 173-175. doi: 10.1038/nrd3680
30. Rasko, D. A., and Sperandio, V. (2010). Anti-virulence strategies to combat bacteria-mediated disease. Nat. Rev. Drug Discov. 9, 117-128. doi: 10.1038/nrd3013
31. Shalapour, S., Font-Burgada, J., Di Caro, G., Zhong, Z., Sanchez-Lopez, E., Dhar, D., et al. (2015). Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature 521, 94-98. doi: 10.1038/nature14395
32. Shulman-Peleg, A., Shatsky, M., Nussinov, R., and Wolfson, H. J. (2007). Spatial chemical conservation of hot spot interactions in protein-protein complexes. BMC Biol. 5:43. doi: 10.1186/1741-7007-5-43
33. Tong, H., Prakash, B. A., Eliassi-Rad, T., Faloutsos, M., and Faloutsos, C. (2012). "Gelling, and melting, large graphs by edge manipulation," in 21st ACM International Conference on Information and Knowledge Management (New York, NY: ACM), 245-254.
34. Varshavsky, A. (1998). Codominant interference, antieffectors, and multitarget drugs. Proc. Natl. Acad. Sci. U.S.A. 95, 2094-2099. doi: 10.1073/pnas.95.5.2094
35. Wang, H., Lee, D. K., Chen, K. Y., Chen, J. Y., Zhang, K., Silva, A., et al. (2015). Mechanism-independent optimization of combinatorial nanodiamond and unmodified drug delivery using a phenotypically driven platform technology. ACS Nano 9, 3332-3344. doi: 10.1021/acsnano.5b00638
36. Wang, Y., Waters, J., Leung, M. L., Unruh, A., Roh, W., Shi, X., et al. (2014). Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 512, 155-160. doi: 10.1038/nature13600
37. Xie, L., Evangelidis, T., Xie, L., and Bourne, P. E. (2011). Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir. PLoS Comput. Biol. 7:e1002037. doi: 10.1371/journal.pcbi.1002037
38. Xie, L., Kinnings, S. L., and Bourne, P. E. (2012). Novel computational approaches to polypharmacology as a means to define responses to individual drugs. Annu. Rev. Pharmacol. Toxicol. 52, 361-379. doi: 10.1146/annurev-pharmtox-010611-134630
39. Yardley, D. A. (2013). Drug resistance and the role of combination chemotherapy in improving patient outcomes. Int. J. Breast Cancer 2013:137414. doi: 10.1155/2013/137414
40. Zbuk, K. M., and Eng, C. (2007). Cancer phenomics: RET and PTEN as illustrative models. Nat. Rev. Cancer 7, 35-45. doi: 10.1038/nrc2037